Dossier assessment

Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A19-94
Last updated

Report documents

  1. Extract of dossier assessment

    Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 361 kB, EN, not accessible
  2. Dossier assessment

    Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 543 kB, DE, not accessible

Dossier assessment

Indication:

Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy

Result of dossier assessment:

Added benefit not proven due to lack of interpretable study data

Project details

Project no.
A19-94
Commission
Commission awarded on 15.11.2019 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94

    Project no.
    A20-33
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form